Wakix is a WPA - period. Thats it. Only with less impressive data and no objective endpoints - plus a drug drug interaction profile that create of problem with pts on polypharmacy. And oh yeah - they will charge over a $100K per year for a drug that did not beat modafinil in EDS?? Payers will be saying WTF. Use Sunosi for EDS. Payers will not cover W in cataplexy - without an indication. BTW - did you ever wonder why the FDA did not allow the indication? - cause their cataplexy data stinks.